🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

392 results for “CIS” Clear

  1. Exercise Training

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 other completed

    1 trial

  2. Functional Precision Oncology

    United Therapeutics Europe Ltd

    Breast Cancer Recurrent

    phase 2 other active

    1 trial

  3. Gemcitabine

    Chongqing Precision Biotech Co., Ltd

    Pancreatic Cancer, Adult

    phase 2 small molecule terminated

    1 trial

  4. Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  5. Gemcitabine plus Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  6. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  7. IFOSFAMIDE, CISPLATIN, PACLITAXEL, METHYLPREDNISOLONE, RANITIDINE, MESNA, APREPITANT, DEXCHLORPHENIRAMINE MALEATE

    Ningbo Cancer Hospital

    Penis carcinoma

    phase 2 small molecule active

    1 trial

  8. IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., PEMETREXED , PACLITAXEL , IMFINZI 50 mg/mL concentrate for solution for infusion., IPH5201, CISPLATIN

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer II, III

    phase 2 small molecule active

    1 trial

  9. IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN

    Ningbo Cancer Hospital

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  10. Ibrutinib, IMBRUVICA 140 mg film-coated tablets, Ibrutinib, Prednison acis 5 mg, Tabletten, Prednison acis 20 mg, Tabletten, Ibrutinib, Prednison acis 50 mg, Tabletten

    AbbVie Deutschland GmbH & Co. KG

    Chronic Graft Versus Host Disease (cGVHD)

    phase 2 small molecule active

    1 trial

  11. Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, AZD0171, Oleclumab, Mycophenolate Mofetil 250 mg Capsules, Inflectra 100 mg powder for concentrate for solution for infusion, CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., volrustomig, CISPLATIN , Monalizumab, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, Rilvegostomig, Inflectra 100 mg powder for concentra

    AstraZeneca AB

    Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Injection of IAH0968+Gemcitabine+Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HER2 Gene Mutation

    phase 2 other active

    1 trial

  13. KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , GEMCITABINE , PACLITAXEL , FAMOTIDINE , MK-2870, PARACETAMOL , CISPLATIN , PEMETREXED , -, -

    Merck Sharp and Dohme

    Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CISPLATIN , CARBOPLATIN

    Istituto Gentili S.r.l.

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  15. KEYTRUDA 25 mg/mL concentrate for solution for infusion., PARACETAMOL , CISPLATIN , FLUOROURACIL , -, MK-2870, CALCIUM FOLINATE , CALCIUM LEVOFOLINATE , -, MK-2870, -

    Merck Sharp and Dohme

    Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  16. Karelizumab combined with etoposide and cisplatin

    Jian Li

    Carcinoma

    phase 2 small molecule active

    1 trial

  17. Kenacort-A 40, suspensie voor injectie 40 mg/ml, JNJ-81201887, Placebo to match Prednisone 20mg, 5mg, JNJ-81201887, Prednison acis 20 mg, Tabletten, Prednison acis 5 mg, Tabletten

    Janssen-Cilag International N.V.

    Geographic Atrophy

    phase 2 small molecule active

    1 trial

  18. LOMUSTINE , Odomzo 200 mg hard capsules, VINCRISTINE, CISPLATIN

    Ningbo Cancer Hospital

    Newly Diagnosed Medulloblastoma

    phase 2 small molecule active

    1 trial

  19. Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830, ETOPOSIDE, Lenvatinib, CISPLATIN, boserolimab, CARBOPLATIN

    Merck Sharp and Dohme

    First-line treatment of participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  20. LiPlaCis

    Allarity Therapeutics

    Phase 1: Advanced or Refractory Solid Tumours

    phase 2 small molecule completed

    1 trial

  21. MK-3120

    Merck Sharp and Dohme

    High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

    phase 2 small molecule active

    1 trial

  22. Melphalan flufenamide (Melflufen)

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  23. NEO-201 in combination with pembrolizumab

    Chongqing Precision Biotech Co., Ltd

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. NPC-1C/NEO-102

    Chongqing Precision Biotech Co., Ltd

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources